Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression

[1]  J. Leitner,et al.  PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells , 2017, Front. Immunol..

[2]  Miles A. Miller,et al.  In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy , 2017, Science Translational Medicine.

[3]  S. Gambhir,et al.  Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model , 2017, Molecular Imaging and Biology.

[4]  Emily B. Ehlerding,et al.  Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab , 2016, The Journal of Nuclear Medicine.

[5]  P. Boutros,et al.  PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC , 2016, PloS one.

[6]  Toshio Shimizu,et al.  Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors , 2016, Investigational New Drugs.

[7]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Levente Kovács,et al.  Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy , 2015, PloS one.

[9]  X. Zang,et al.  New immunotherapies targeting the PD-1 pathway. , 2015, Trends in pharmacological sciences.

[10]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[11]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[12]  A. Iagaru,et al.  Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma. , 2015, Molecular Imaging.

[13]  S. Gambhir,et al.  Radiation Dosimetry Study of [89Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography , 2015, Molecular Imaging and Biology.

[14]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[15]  R. Carvajal,et al.  Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy , 2013, Expert opinion on biological therapy.

[16]  C. Mu,et al.  Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study , 2012 .

[17]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Wu,et al.  Positive progress in immunoPET--not just a coincidence. , 2010, Cancer biotherapy & radiopharmaceuticals.

[19]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[20]  R. Kroczek,et al.  Dendritic Cells Support Homeostatic Expansion of Foxp3+ Regulatory T Cells in Foxp3.LuciDTR Mice , 2010, The Journal of Immunology.

[21]  J. Kirkwood,et al.  PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1 , 2009, The Journal of Immunology.

[22]  Icrp,et al.  Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. , 2008, Annals of the ICRP.

[23]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[24]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[25]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[26]  野見 武男.  Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer , 2007 .

[27]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[28]  T. Witzig.  Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. , 2004, Drugs of today.

[29]  Michael G Stabin,et al.  PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT , 2003, Health physics.

[30]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[31]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[33]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[34]  Jack Valentin,et al.  Radiation dose to patients from radiopharmaceuticals , 1991 .

[35]  Icrp.  Radiation dose to patients from radiopharmaceuticals , 1988 .

[36]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[37]  W. Beierwaltes,et al.  Radiation dosimetry of 131I-19-iodocholesterol. , 1973, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.